Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

3(60.0%)

Phase 4

2(40.0%)

5Total

N/A(3)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07118124Not ApplicableActive Not Recruiting

Pediatric Adhesion and New Dermal Approach Study

Role: lead

NCT07027969Phase 4Not Yet Recruiting

Metabolic Surgery for Atrial Fibrillation Elimination

Role: collaborator

NCT07205367Not ApplicableActive Not Recruiting

Validation Study: Extended Wear Performance of the Zio Monitor - SHASTA II

Role: lead

NCT03168529Phase 4Terminated

Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit

Role: collaborator

NCT04056715Completed

Extended ECG Monitoring in HCM Patients

Role: lead

NCT02392754Not ApplicableCompleted

Home-Based Screening for Early Detection of Atrial Fibrillation in Primary Care Patients Aged 75 Years and Older

Role: collaborator

NCT01559246Completed

True Continuous ECG Monitoring (TCEM Study)

Role: lead

All 7 trials loaded